DIVIDEND ANNOUNCEMENT: Ord Cl A/Royalty Pharma plc (NASDAQ:RPRX) on 04/17/2026 declared a dividend of $0.2350 per share

Ord Cl A/Royalty Pharma plc (NASDAQ:RPRX) on 04/17/2026 declared a dividend of $ 0.2350 per share payable on June 10, 2026 to shareholders of record as of May 15, 2026.

Ord Cl A/Royalty Pharma plc (NASDAQ:RPRX) has paid dividends since 1970, has a current dividend yield of 1.8770627975% and has increased its dividends for 5 successive years.

Ord Cl A/Royalty Pharma plc's market cap is $ 20,769,753,120 and has a PE ratio of 27.24. The stock price closed yesterday at $ 48.48 and has a 52 week low/high of $ 31.58 and $ 49.06.

Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. Co. collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Novartis' Promacta, Pfizer's Nurtec ODT and Gilead's Trodelvy, and 14 development-stage product candidates.

For more information on Ord Cl A/Royalty Pharma plc click here.